Crown Reserve Acquisition Corp. I（CRAC）股票分析

AI 分析 of Crown Reserve Acquisition Corp. I (CRAC)

持有

Crown Reserve Acquisition Corp. I (CRAC) is currently priced at 10.27, which is just below its 52-week high of 10.30, indicating limited upside potential. The RSI is at 54.98, suggesting the stock is neither overbought nor oversold, which is neutral. However, the forward P/E ratio is 0, indicating uncertainty about future earnings, and the current ratio is low at 0.03, which raises concerns about liquidity. The stock has shown a year-to-date change of +3.32%, but with no significant positive catalysts or insider buying activity, it may be prudent to hold rather than buy at this time.

估值指標

Crown Reserve Acquisition Corp. I（CRAC）目前預期本益比為 0.00，5 年平均預期本益比為。

預期本益比

5 年均值 P/E

目前P/E

0.00

預期 EV/EBITDA

5 年均值 EV/EBITDA

目前EV/EBITDA

0.00

預期股價營收比

5 年均值 P/S

目前P/S

0.00

持有 CRAC 的大戶

W

W. R. Berkley Corporation

+ 持有CRAC

-1.34%

3個月報酬率

P

Polar Asset Management Partners Inc.

+ 持有CRAC

-2.91%

3個月報酬率

CRAC 常見問題 —— 由 Alphio AI 解答

Crown Reserve Acquisition Corp I is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. It focused industries include pharma, medical technology and medical equipment, and healthcare information technology (IT) industries. The Company is not engaged in any business operation and does not have any revenues. It operates in the Financials sector.

Crown Reserve Acquisition Corp. I (CRAC) is currently priced at 10.27, which is just below its 52-week high of 10.30, indicating limited upside potential. The RSI is at 54.98, suggesting the stock is neither overbought nor oversold, which is neutral. However, the forward P/E ratio is 0, indicating uncertainty about future earnings, and the current ratio is low at 0.03, which raises concerns about liquidity. The stock has shown a year-to-date change of +3.32%, but with no significant positive catalysts or insider buying activity, it may be prudent to hold rather than buy at this time.